Pathologist-led interpretation of complex diagnostic data is valuable wherever a structured result needs to become a defensible clinical decision. That includes clinical trial central labs, biopharma research operations, contract research organizations, and integrated health systems.
Clinical trials in infectious disease, oncology, immunology, and rare disease often hinge on how diagnostic results are interpreted across enrolled sites. When interpretation varies between sites, the data variance becomes the story instead of the therapy.
AICC provides centralized pathologist consultation for sponsor trials: consistent interpretation across every site, every case, every visit. Board-certified pathologists review the structured molecular or laboratory data, apply the protocol-specified clinical framework, and return a signed consultation that aligns with the sponsor's reporting requirements.
Used alongside a sponsor's central laboratory or as a specialist interpretation overlay on existing site-level testing.
Contract research organizations often manage diagnostic and laboratory operations for sponsor trials but do not maintain a board-certified pathology team for clinical interpretation. Building one is expensive, hiring one is competitive, and using one inconsistently introduces variability the sponsor will not accept.
AICC operates as a specialist interpretation partner for CROs: a credentialed pathology team available on a per-study basis, integrated into the CRO's existing data and reporting workflow, branded as the CRO requires. The CRO maintains the sponsor relationship. AICC supplies the specialist judgment behind the report.
This is the same engine-under-the-hood model we run for clinical laboratories, applied to the trial context.
Health systems often run molecular diagnostics across multiple sites, multiple instruments, and multiple provider workflows. The result is a flood of complex structured data with uneven interpretive support. Some providers know what a resistance gene cascade means. Most do not. The system-wide answer is often empirical broad-spectrum therapy, which is exactly what the system's stewardship committee is trying to prevent.
AICC fits in as a system-wide pathologist consultation layer. Every complex case across every site gets the same standard of interpretation: a board-certified pathologist's signed recommendation, anchored in current guidance, returned to the ordering provider in the system's reporting environment.
This is particularly valuable for systems with antimicrobial stewardship goals, broad geographic footprints, or rural and community sites that do not have specialist consultation available locally.
Whether the request comes from a clinical laboratory, a sponsor trial, a CRO, or a health system, the underlying service is the same: a credentialed pathologist reviews the case and signs the consultation. The discipline does not change.
Every consultation recommends the narrowest effective approach the evidence supports. The standard is the same across contexts because clinical responsibility is the same across contexts.
Reports arrive branded as the laboratory, the CRO, the sponsor, or the health system. AICC is the specialist underneath, not the brand on the page. The partner relationship belongs to the partner.
Integration matches the operational reality of the partner. A clinical lab's reporting environment is different from a CRO's data system, which is different from a health system's EHR. The consultation flows in wherever the partner already operates.